Qiagen N.V. (NASDAQ: QGEN) and AC Immune SA (NASDAQ:ACIU) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends.
This is a summary of current ratings and target prices for Qiagen N.V. and AC Immune SA, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AC Immune SA||0||0||3||0||3.00|
Qiagen N.V. presently has a consensus price target of $32.56, suggesting a potential upside of 1.13%. AC Immune SA has a consensus price target of $21.67, suggesting a potential upside of 121.77%. Given AC Immune SA’s stronger consensus rating and higher probable upside, analysts plainly believe AC Immune SA is more favorable than Qiagen N.V..
Earnings and Valuation
This table compares Qiagen N.V. and AC Immune SA’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Qiagen N.V.||$1.36 billion||5.40||$443.36 million||$0.33||98.96|
|AC Immune SA||$5.74 million||97.10||-$34.13 million||N/A||N/A|
Qiagen N.V. has higher revenue and earnings than AC Immune SA.
This table compares Qiagen N.V. and AC Immune SA’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AC Immune SA||N/A||N/A||N/A|
Institutional and Insider Ownership
63.0% of Qiagen N.V. shares are held by institutional investors. Comparatively, 18.1% of AC Immune SA shares are held by institutional investors. 9.0% of Qiagen N.V. shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Qiagen N.V. beats AC Immune SA on 8 of the 11 factors compared between the two stocks.
About Qiagen N.V.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company’s automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
About AC Immune SA
AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.